The Structure of HPK1 Kinase Domain: To Boldly Go Where No Immuno-Oncology Drugs Have Gone Before
Abstract
No abstract availableKeywords
This publication has 10 references indexed in Scilit:
- Hematopoietic Progenitor Kinase-1 Structure in a Domain-Swapped DimerStructure, 2019
- The Kinase Activity of Hematopoietic Progenitor Kinase 1 Is Essential for the Regulation of T Cell FunctionCell Reports, 2018
- Cancer immunotherapy using checkpoint blockadeScience, 2018
- Big opportunities for small molecules in immuno-oncologyNature Reviews Drug Discovery, 2015
- Molecular and cellular insights into T cell exhaustionNature Reviews Immunology, 2015
- HPK1 as a novel target for cancer immunotherapyImmunologic Research, 2012
- Hematopoietic progenitor kinase 1 is a critical component of prostaglandin E2-mediated suppression of the anti-tumor immune responseCancer Immunology, Immunotherapy, 2009
- Hematopoietic Progenitor Kinase 1 Is a Negative Regulator of Dendritic Cell ActivationThe Journal of Immunology, 2009
- Hematopoietic progenitor kinase 1 negatively regulates T cell receptor signaling and T cell–mediated immune responsesNature Immunology, 2006
- HPK1 Is Activated by Lymphocyte Antigen Receptors and Negatively Regulates AP-1Immunity, 2000